<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00310336</url>
  </required_header>
  <id_info>
    <org_study_id>EKBB 37/06</org_study_id>
    <nct_id>NCT00310336</nct_id>
  </id_info>
  <brief_title>Chronic Hepatitis C Non-Responder Study With AdoMet and Betaine</brief_title>
  <official_title>Chronic Hepatitis C: Treatment of (Peg)Interferon Alpha - Ribavirin Non-Responders With Pegylated Interferon alpha2b, Ribavirin, AdoMet and Betaine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <brief_summary>
    <textblock>
      50-60% of patients with chronic hepatitis C are not cured by treatment with pegylated IFNα&#xD;
      plus ribavirin.&#xD;
&#xD;
      Retreatment of non-responders of previous (pegylated) IFNα plus ribavirin therapies with&#xD;
      pegylated IFNα plus ribavirin results in a sustained response in less than 10% of the&#xD;
      patients.&#xD;
&#xD;
      Extensive analysis of IFNα signaling in cells expressing HCV proteins, in transgenic mice&#xD;
      expressing HCV proteins, and in liver biopsies from patients with chronic hepatitis C point&#xD;
      to STAT1 methylation as an important posttranslational modification targeted by HCV to&#xD;
      inhibit IFNα signaling.&#xD;
&#xD;
      STAT1 methylation can be increased and IFNα can be improved by adding AdoMet and betaine.&#xD;
&#xD;
      The study is designed to test the hypothesis that a combination treatment with pegylated&#xD;
      IFNα2b, ribavirin, AdoMet and betaine is superior to the current standard combination therapy&#xD;
      with pegylated IFNα plus ribavirin.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained response rate</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Early virologic response after 12 weeks of therapy with PegIntron, Rebetol, AdoMet and betaine.</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hepatitis C</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-adenosyl-L-methionine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>betaine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegylated interferon alpha2b</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ribavirin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female between 18 and 65 years.&#xD;
&#xD;
          -  Non-responders in previous treatments with IFNα plus ribavirin or pegylated IFNα plus&#xD;
             ribavirin.&#xD;
&#xD;
          -  Elevated ALT-levels on at least two occasions during &gt;6 months preceding entry.&#xD;
&#xD;
          -  Detection of HCV RNA in serum (PCR).&#xD;
&#xD;
          -  Compensated liver disease (Child-Pugh A) and a Child-Pugh score &lt;5.&#xD;
&#xD;
          -  The following minimal hematologic and biochemical criteria:&#xD;
&#xD;
          -  Hemoglobin for males and females &gt;11g/dl&#xD;
&#xD;
          -  Absolute Neutrophil count &gt;1500 cells/mm3&#xD;
&#xD;
          -  Platelets &gt;75'000/mm3&#xD;
&#xD;
          -  HBs Ag negative.&#xD;
&#xD;
          -  ANA &lt;1:320, and no evidence for autoimmune hepatitis.&#xD;
&#xD;
          -  α-Fetoprotein &lt;50μg/l (when between upper limit of normal and 50μg/l,&#xD;
             ultrasonographical exclusion of hepatocellular carcinoma (HCC) is needed).&#xD;
&#xD;
          -  Fasting blood glucose within normal limits, if history of diabetes or hypertension, a&#xD;
             pre-therapy ocular examination is indicated.&#xD;
&#xD;
          -  TSH within normal limits or adequately controlled.&#xD;
&#xD;
          -  Negative urine or blood pregnancy test (for women of childbearing potential)&#xD;
             documented within the 2-3 week period prior to the first dose of study drug.&#xD;
             Additionally, all fertile males and females must be using effective contraception&#xD;
             during treatment and during the 6 months after treatment end. This may include, but is&#xD;
             not limited to, using birth control pills, IUDs, condoms, diaphragms, or implants,&#xD;
             being surgically sterilized, or being in a post-menopausal state.&#xD;
&#xD;
          -  Willingness to give written informed consent and willingness to participate to and&#xD;
             comply with the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women with ongoing pregnancy or breast feeding.&#xD;
&#xD;
          -  Positive test at screening for anti-HAV IgM Ab, HBsAg, anti-HBc IgM Ab, HBe Ag.&#xD;
&#xD;
          -  Positive test at screening for HIV.&#xD;
&#xD;
          -  History or other evidence of a medical condition associated with chronic liver disease&#xD;
             other than HCV (e.g., hemochromatosis, autoimmune hepatitis, alcoholic liver disease,&#xD;
             toxin exposures).&#xD;
&#xD;
          -  Hypersensitivity to study drugs.&#xD;
&#xD;
          -  Participation in any other clinical trial within 30 days of entry into this protocol.&#xD;
&#xD;
          -  Treatment with any investigational drug within 30 days of entry into this protocol.&#xD;
&#xD;
          -  History or evidence of decompensated liver disease (Child-Pugh B/C) and a Child-Pugh&#xD;
             score &gt;5. Ascites, coagulopathy, hyperbilirubinemia, hepatic encephalopathy, or&#xD;
             hypoalbuminemia and a Child-Pugh score &gt;5 are conditions consistent with decompensated&#xD;
             liver disease.&#xD;
&#xD;
          -  History or other evidence of bleeding from esophageal varices or other conditions&#xD;
             consistent with decompensated liver disease.&#xD;
&#xD;
          -  Hepatocellular carcinoma (HCC) or α-Fetoprotein &gt;50μg/l.&#xD;
&#xD;
          -  Patients with organ transplants other than cornea and hair transplant.&#xD;
&#xD;
          -  Therapy with any antisystemic or immunomodulatory treatment (including&#xD;
             supra-physiologic doses of steroids or radiation) &lt;6 months prior the first dose of&#xD;
             study drug&#xD;
&#xD;
          -  Hemoglobinopathy (e.g. thalassemia) or any other cause of or tendency for hemolysis.&#xD;
&#xD;
          -  Any known preexisting medical condition that could interfere with the patient's&#xD;
             participation in and completion of the study such as:&#xD;
&#xD;
          -  Preexisting psychiatric condition, especially depression, or a history of severe&#xD;
             psychiatric disorder, such as major psychosis, suicidal ideation and/or suicidal&#xD;
             attempts (based on a mandatory psychiatric advice).&#xD;
&#xD;
          -  CNS trauma or active seizure disorders requiring medication.&#xD;
&#xD;
          -  Significant cardiovascular dysfunction.&#xD;
&#xD;
          -  Poorly controlled diabetes mellitus.&#xD;
&#xD;
          -  Renal dysfunction, i.e. serum creatinine levels &gt;1.5 times upper limit of normal.&#xD;
&#xD;
          -  Autoimmune diseases.&#xD;
&#xD;
          -  Evidence of severe retinopathy (e.g. CMV retinitis, macular degeneration).&#xD;
&#xD;
          -  Any medical condition requiring, or likely to require during the course of the study,&#xD;
             chronic systemic administration of steroids.&#xD;
&#xD;
          -  Clinical gout.&#xD;
&#xD;
          -  Important substance abuse (alcohol &gt;80 g/d, i.v. drugs etc.).&#xD;
&#xD;
          -  Active opportunistic infections.&#xD;
&#xD;
          -  Non-Hodgkin lymphoma or Hodgkin lymphoma.&#xD;
&#xD;
          -  Kaposi sarcoma.&#xD;
&#xD;
          -  Inability or unwillingness to provide informed consent or abide by the requirements of&#xD;
             the study.&#xD;
&#xD;
          -  Male partners of pregnant women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markus H Heim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Basel, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <state>BS</state>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Duong FH, Christen V, Filipowicz M, Heim MH. S-Adenosylmethionine and betaine correct hepatitis C virus induced inhibition of interferon signaling in vitro. Hepatology. 2006 Apr;43(4):796-806.</citation>
    <PMID>16557551</PMID>
  </reference>
  <reference>
    <citation>Duong FH, Christen V, Berke JM, Penna SH, Moradpour D, Heim MH. Upregulation of protein phosphatase 2Ac by hepatitis C virus modulates NS3 helicase activity through inhibition of protein arginine methyltransferase 1. J Virol. 2005 Dec;79(24):15342-50.</citation>
    <PMID>16306605</PMID>
  </reference>
  <reference>
    <citation>Duong FH, Filipowicz M, Tripodi M, La Monica N, Heim MH. Hepatitis C virus inhibits interferon signaling through up-regulation of protein phosphatase 2A. Gastroenterology. 2004 Jan;126(1):263-77.</citation>
    <PMID>14699505</PMID>
  </reference>
  <reference>
    <citation>Blindenbacher A, Duong FH, Hunziker L, Stutvoet ST, Wang X, Terracciano L, Moradpour D, Blum HE, Alonzi T, Tripodi M, La Monica N, Heim MH. Expression of hepatitis c virus proteins inhibits interferon alpha signaling in the liver of transgenic mice. Gastroenterology. 2003 May;124(5):1465-75.</citation>
    <PMID>12730885</PMID>
  </reference>
  <reference>
    <citation>Heim MH, Moradpour D, Blum HE. Expression of hepatitis C virus proteins inhibits signal transduction through the Jak-STAT pathway. J Virol. 1999 Oct;73(10):8469-75.</citation>
    <PMID>10482599</PMID>
  </reference>
  <verification_date>October 2010</verification_date>
  <study_first_submitted>March 31, 2006</study_first_submitted>
  <study_first_submitted_qc>March 31, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2006</study_first_posted>
  <last_update_submitted>October 27, 2010</last_update_submitted>
  <last_update_submitted_qc>October 27, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2010</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferon alpha-2</mesh_term>
    <mesh_term>Peginterferon alfa-2b</mesh_term>
    <mesh_term>Betaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

